IBM
67
2
ALLE
48
2
HSIC
62
-3
PX
55
2
VMC
59
2
PEG
50
4
GIS
54
2
TSN
47
3
VLO
40
-2
UPS
40
2
MAS
63
3
AAPL
55
2
BK
77
2
TRIP
52
2
NKE
36
6
GWW
65
3
OMC
55
-7
NVDA
57
-2
GS
78
2
MCD
46
4
IBM
67
2
ALLE
48
2
HSIC
62
-3
PX
55
2
VMC
59
2
PEG
50
4
GIS
54
2
TSN
47
3
VLO
40
-2
UPS
40
2
MAS
63
3
AAPL
55
2
BK
77
2
TRIP
52
2
NKE
36
6
GWW
65
3
OMC
55
-7
NVDA
57
-2
GS
78
2
MCD
46
4
Financhill
Back

Coherus Oncology, Inc. 10K Form

Sell
48

CHRS
Coherus Oncology, Inc.

Last Price:
$1.35
Seasonality Move:
0.05%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive CHRS News And Ratings

See the #1 stock for the next 7 days that we like better than CHRS

CHRS Financial Statistics

Sales & Book Value

Annual Sales: $267M
Cash Flow: $-46.3M
Price / Cash Flow: 189.35
Annual Sales: $0.76
Price / Book: 1.86

Profitability

EPS (TTM): -1.58570
Net Income (TTM): $-187.5M
Gross Margin: $144.1M
Return on Equity: 0%
Return on Assets: -40.99%

Coherus Oncology, Inc. Earnings Forecast

Key Coherus Oncology, Inc. Financial Ratios

  • The Gross Profit Margin over the past 19 years for CHRS is 53.99%.
  • The Selling, General & Administrative Expenses for CHRS have been equal to 62.83% of Gross Profit Margin.
  • The Research & Development expenses have been 32.99% of Revenue.
  • The Interest Expense is 95.27% of Operating Income.
  • The Net Earning history of CHRS is 10.68% of Total Revenues.
  • Per Share Earnings over the last 19 years have been positive in 11 years.

Coherus Oncology, Inc. Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: CHRS
CUSIP: 19249H
Website: coherus.com

Debt

Debt-to-Equity Ratio: 0.62
Current Ratio: 1.24
Quick Ratio: 0.54

Price-to-Earnings

Trailing P/E Ratio: 5.44
Forward P/E Ratio: 10.81

CHRS Technical Analysis vs Fundamental Analysis

Sell
48
Coherus Oncology, Inc. (CHRS) is a Sell

Is Coherus Oncology, Inc. a Buy or a Sell?